Literature DB >> 7117355

The metabolic disposition of flucloxacillin in patients with impaired kidney function.

H H Thijssen, J Wolters.   

Abstract

The fate of flucloxacillin and its active metabolite hydroxyflucloxacillin was studied in a group of patients with impaired kidney function. Flucloxacillin was administered orally or intravenously. Peak levels of hydroxyflucloxacillin were obtained between 150 and 250 min after the administration of flucloxacillin. The plasma concentrations obtained after a therapeutic dose of flucloxacillin were well above the concentration (i.e. 1-2 microgram/ml) generally considered to be the effective minimum for isoxalyl penicillins. The plasma half life of the metabolite was twice as long as that of flucloxacillin (295 min and 154 min, respectively). The nonprotein-bound fraction of hydroxyflucloxacillin in plasma from patients was twice as large as that of its parent compound (16.2 vs. 8.1%). This was also observed in normal human plasma, although protein binding in the latter was higher than in uraemic plasma. Some accumulation of hydroxyflucloxacillin may occur during flucloxacillin therapy with dosage intervals of 6 h.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7117355     DOI: 10.1007/bf00542548

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

2.  Fate of oral 35S-cloxacillin in man.

Authors:  K Hellström; A Rosén; A Swahn
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

3.  Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum.

Authors:  C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1966 Mar-Apr       Impact factor: 6.875

4.  Prediction of the concentration of penicillins in ascitic fluid from serum kinetics and protein binding of the antibiotics in serum and ascitic fluid of dogs.

Authors:  D N Gerding; L R Peterson; J K Salomonson; W H Hall; E A Schierl
Journal:  J Infect Dis       Date:  1978-08       Impact factor: 5.226

5.  Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis.

Authors:  E H Nauta; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

Review 6.  Renal failure, drug pharmacokinetics and drug action.

Authors:  J Fabre; L Balant
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Active metabolites of isoxazolylpencillins in humans.

Authors:  H H Thijssen; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

8.  Comparative penetration of various cephalosporins into inflammatory exudate.

Authors:  I C Guerrero; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

9.  Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption.

Authors:  M Cole; M D Kenig; V A Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

10.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

View more
  9 in total

1.  Re: B. L. Røder, et al.: Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration (Infection 23 [1995] 107-112)

Authors:  H H Thijssen
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

2.  Flucloxacillin kinetics in newborn infants.

Authors:  L Herngren
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Flucloxacillin kinetics in newborn infants.

Authors:  H H Thijssen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

5.  Pharmacokinetics and distribution of flucloxacillin in pacemaker patients.

Authors:  P Anderson; G Bluhm; M Ehrnebo; L Herngren; B Jacobson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects.

Authors:  Mathilde Neuville; Najoua El-Helali; Eric Magalhaes; Aguila Radjou; Roland Smonig; Jean-François Soubirou; Guillaume Voiriot; Alban Le Monnier; Stéphane Ruckly; Lila Bouadma; Romain Sonneville; Jean-François Timsit; Bruno Mourvillier
Journal:  Ann Intensive Care       Date:  2017-03-22       Impact factor: 6.925

7.  Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations.

Authors:  Nynke G L Jager; Reinier M van Hest; Jiao Xie; Gloria Wong; Marta Ulldemolins; Roger J M Brüggemann; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

8.  In healthy volunteers, taking flucloxacillin with food does not compromise effective plasma concentrations in most circumstances.

Authors:  Sharon J Gardiner; Philip G Drennan; Ronald Begg; Mei Zhang; Jared K Green; Heather L Isenman; Richard J Everts; Stephen T Chambers; Evan J Begg
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

9.  Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.

Authors:  Stefan J Dekker; Floor Dohmen; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.